Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy

Zoon K . www.fda.go 2000.

Somia N, Verma IM . Gene therapy: trial and tribunals. Nat Rev 2000; 1: 91–99.

Bromberg JS, Debruyne LA, Qin L . Interactions between the immune system and gene therapy vectors: bidirectional regulation of response and expression. Adv Immunol 1998; 69: 353–409.

Hackett NR, Kaminsky SM, Sonmdhi D, Crystal RG . Anticector and antitransgene host responses in gene therapy. Curr Opin Mol Ther 2000; 2: 376–382.

Yang Y et al. Cellular immunity fo viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407–4411.

Tripathy SK BH, Goldwasser E, Leiden JM . Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996; 2: 545–550.

Banchereau J, Steinman RM . Dendritic cells and the control of immunity. Nature 1998; 392: 245–252.

Janeway CA, Medzhitov R . The role of innate immunity in the adpative immune response. Sem Immunol 1998; 10: 349–350.

Gallucci S, Matzinger P . Danger signals: SOS to the immune system. Curr Opin Immunol 2001; 13: 114–119.

Akira S, Takeda K, Kaisho T . Toll-like ceptros: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2: 675–680.

Sallusto F, Lanzavecchia A . Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol Rev 2000; 177: 134–140.

Bluestone JA . New perspectives of CD28-B7-mediated T cell costimulation. Immunity 1995; 2: 555–559.

Schmitz H, Wigand R, Heinrich W . Worldwide epidemiology of human adenovirus infections. Am J Epidemiol 1983; 117: 455–466.

Wold SM, Tollefson AE, Hermiston TW . Strategies of immune modulation by adenoviruses. In: McFadden G (ed). Viroceptors, Virokines and Related Immune Modulators Encoded by DNA Viruses. R.G. Landes Company: 1994, pp 147–185.

Chirmule N et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Therapy 1999; 6: 1574–1583.

Mack CA et al. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 1997; 8: 99–109.

Zabner J et al. A chimeric type 2 adenovirus vector with a type 17 fiber enhances gene transfer to human airway epithelia. J Virol 1999; 73: 8689–8695.

Farina SF et al. Replication-defective vector based on a chimpanzee adenovirus. J Virol 2001; 75: 11603–11613.

Klonjkowski B et al. A recombinant E1-deleted canine adenoviral vector capable of transduction and expression of a transgene in human-derived cells and in vivo. Hum Gene Ther 1997; 8: 2103–2115.

Chen HH et al. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci 1997; 94: 1645–1650.

Morsy MA et al. An adenoviral vector deleted of all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA 1998; 95: 7866–7871.

Morral N et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 1999; 96: 12816–12821.

Rodriguez R et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997; 57: 2559–2563.

Bischoff JR et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373–376.

Kirn DH, Martuza RL, Zwibel J . Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001; 7: 781–787.

Breyer B et al. Adenoviral vector mediated gene transfer in human gene therapy. Curr Gene Ther 2001; 1: 149–162.

Kay MA, Glorioso JC, Naldini L . Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7: 33–40.

Monahan PE, Samulski RJ . Adeno-associated virus vectors for gene therapy: more pros than cons? Mol Med Today 2000; 6: 433–440.

Dutheil N, Shi F, Dupressoir T, Linden RM . Adeno-associated virus site-specifically integrates into a muscle-specific DNA region. Proc Natl Acad Sci USA 2000; 97: 4862–4866.

Young Jr SM, Samulski RJ . Adeno-associated virus (AAV) site-specific recombination does not require a Rep-dependent origin of replication within the AAV terminal repeat. Proc Natl Acad Sci USA 2001; 98: 13525–13530.

Rabinowitz JE, Samulski RJ . Building a better vector: the manipulation of AAV virions. Virology 2000; 278: 301–308.

Gao GP et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002; 99: 11854–11859.

Xiao X, Li J, McCown TJ, Samulski RJ . Gene transfer by adeno-associated virus vectors into the central nervous system. Exp Neurol 1997; 144: 113–124.

Xiao X, Li J, Samulski RJ . Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996; 70: 8098–8108.

Herzog RW et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999; 5: 56–63.

Fisher KJ et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 1997; 3: 306–312.

Kessler PD et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 1996; 93: 14082–14087.

Snyder RO et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med 1999; 5: 64–70.

Ferrari FK, Samulski T, Shenk T, Samulski RJ . Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996; 70: 3227–3234.

Malik AK et al. Kinetics of recombinant adeno-associated virus-mediated gene transfer. J Virol 2000; 74: 3555–3565.

Raper SE et al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther 2002; 1: 163–175.

Mickelson CA . Recombinant DNA Advisory Committee. Hum Gene Ther 2000; 11: 1591–1621.

Crystal RG et al. Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum Gene Ther 2002; 13: 65–100.

Harvey BG et al. Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther 2002; 13: 15–63.

Ben-Gary H et al. Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes. Mol Ther 2002; 6: 287–297.

Reid T et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Therapy 2001; 8: 1618–1626.

Brusilow SW, Maestri NE . Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv Pediatr 1996; 43: 127–170.

Lozier JN et al. Toxicity of a first-generation adenoviral vector in rhesus macaques. Hum Gene Ther 2002; 13: 113–124.

Zhang Y, Chirmule N, Wilson JM . Acute cytokine responses to systemic adenovirus vector is mediated by dendritic cells and macrophages. Mol Ther 2001; 3: 697–707.

Zaiss A et al. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 2002; 76: 4580–4590.

Varnavski AN et al. Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity. J Virol 2002; 76: 5711–5719.

Kafri T et al. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci USA 1998; 95: 11377–11382.

Croyle MA, Chirmule N, Zhang Y, Wilson JM . “Stealth” adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol 2001; 75: 4792–4801.

O'Riordan CR et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 1999; 10: 1349–1358.

Croyle MA, Chirmule N, Zhang Y, Wilson JM . PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther 2002; 13: 1887–1900.

Jooss K, Yang Y, Fisher KJ, Wilson JM . Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998; 72: 4212–4223.

Zhang Y, Chirmule N, Gao G, Wilson J . CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells. J Virol 2000; 74: 8003–8010.

Cordier L et al. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum Gene Ther 2001; 12: 205–215.

Ponnazhagan S, Mahendra G, Curiel DT, Shaw DR . Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy. J Virol 2001; 75: 9493–9501.

Manning WC et al. Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D. J Virol 1997; 71: 7960–7962.

Brockstedt DG et al. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin Immunol 1999; 92: 67–75.

During MJ et al. An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science 2000; 287: 1453–1460.

Sarukhan A et al. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors. J Virol 2001; 75: 269–277.

Prasad SA et al. Recombinant adenoviruses induce CD8 T cell responses to an inserted protein whose expression is limited to nonimmune cells. J Immunol 2001; 166: 4809–4812.

Kurts C et al. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med 1998; 188: 409–414.

Snyder RO et al. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum Gene Ther 1997; 8: 1891–1900.

Camargo FD et al. Germline incorporation of a replication-defective adenoviral vector in mice does not alter immune responses to adenoviral vectors. Mol Ther 2000; 2: 496–504.

DeMatteo RP et al. Long-lasting adenovirus transgene expression in mice through neonatal intrathymic tolerance induction without the use of immunosuppression. J Virol 1997; 71: 5330–5335.

Schneider H et al. Sustained delivery of therapeutic concentrations of human clotting factor IX – a comparison of adenoviral and AAV vectors administered in utero. J Gene Med 2002; 4: 46–53.

Ge Y, Powell S, Van Roey M, McArthur JG . Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX. Blood 2001; 97: 3733–3737.

Chao H, Walsh CE . Induction of tolerance to human factor VIII in mice. Blood 2001; 97: 3311–3312.

Molnar-Kimber KL et al. Impact of pre-existing and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 1998; 9: 2121–2133.

Anand V et al. Additional transduction events after subretinal readministration of recombinant adeno-associated virus. Hum Gene Ther 2000; 11: 449–457.

Chirmule N et al. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J Virol 2000; 74: 2420–2425.

Xiao W et al. Route of administration determines induction of T cell independent humoral responses to adeno-associated virus vectors. Mol Ther 2000; 1: 323–329.

Yang Y et al. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J Virol 1996; 70: 6370–6377.

Chen Y, Yu DC, Charlton D, Henderson DR . Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy. Hum Gene Ther 2000; 11: 1553–1567.

Rahman A et al. Specific depletion of human anti-adenovirus antibodies facilitates transduction in an in vivo model for systemic gene therapy. Mol Ther 2001; 3: 768–778.

Kremer EJ, Boutin S, Chillon M, Danos O . Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer. J Virol 2000; 74: 505–512.

Jooss K, Turka LA, Wilson JM . Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Ther 1998; 5: 309–319.

Kay MA et al. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc Natl Acad Sci USA 1997; 94: 4686–4691.